ASPE analyzed Part D prescription drug event data from 2016 to estimate spending on brand drugs with generic therapeutic equivalents.
Prescription Drugs
Reports
Displaying 71 - 80 of 103. 10 per page. Page 8.
Advanced SearchASPE Data Point
Data Point: Savings Available Under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D
Observations on Trends in Prescription Drug Spending
Key findings • Expenditures on prescription drugs are rising and are projected to continue to rise faster than overall health spending thereby increasing this sector’s share of health care spending.
Medicare Part B Drugs: Pricing and Incentives
Medicare Part B covers infusible and injectable drugs and biologics administered in physician offices and hospital outpatient departments; as well as certain other drugs required by law provided by suppliers such as pharmacies The Part B payment method provides weak incentives for physicians to consider value – that is choose the lowest cost therapy to effectively treat a patient.
Examination of Clinical Trial Costs and Barriers for Drug Development
Pharmaceutical companies conduct clinical trials for many reasons. The most obvious goal of clinical trials is to demonstrate safety and efficacy to gain Food and Drug Administration (FDA) approval. FDA provides guidance to developers about what constitutes acceptable clinical trials and appropriate outcomes.
Expanding the Use of Generic Drugs
Dramatic growth in the use of generic drugs has generated substantial savings for American consumers. To examine how the Department of Health and Human Services (HHS) can encourage the use of generic drugs, the Assistant Secretary for Planning and Evaluation (ASPE) examined barriers to, and opportunities for, expanding the use of generic drugs.
Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
U.S. Department of Health and Human Services
A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available.